Monitor for the FDA PMA submission and review timeline, as approval could open a major U.S. market opportunity in VT ablation. The strong clinical data may attract partnership or acquisition interest given the company's $34M market cap.
Price Chart
Executive Summary
Adagio Medical announced positive pivotal results from its FULCRUM-VT IDE trial for the vCLAS Ventricular Ablation System, showing 84% freedom from ICD shock and 59% freedom from VT recurrence at 6 months. The data will support a U.S. FDA Premarket Approval application and represent a significant clinical milestone for treating ventricular tachycardia.
Key Facts
- FULCRUM-VT trial met safety and effectiveness endpoints with 84% freedom from ICD shock and 59% freedom from VT recurrence at 6 months
- Results were consistent across ischemic and non-ischemic cardiomyopathy patients, a first for endocardial-only ablation
- The trial enrolled 209 patients across 20 U.S. and Canadian centers in a prospective, single-arm study
- Data will be used to support a U.S. FDA Premarket Approval (PMA) application for the vCLAS system
- The vCLAS system is CE Marked and available in Europe but limited to investigational use in the U.S.
Financial Impact
Potential for significant future revenue growth upon FDA approval, though no immediate financial impact is quantified in the filing
Risk Factors
- FDA may not approve the device despite positive trial results
- Commercial execution risk upon potential approval
- Competition from established ablation technologies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-048833 |
| Document: tm2612751d1_ex99-1.htm | 0001104659-26-048833 |
| Document: 0001104659-26-048833-index-headers.html | 0001104659-26-048833 |
| Document: 0001104659-26-048833-index.html | 0001104659-26-048833 |
| Document: 0001104659-26-048833.txt | 0001104659-26-048833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEF 14A | $0.1253 $0.1208 | ▼ −3.59% | ▼ −2.44% | $0.1030 (−17.80%) |
Oct 1, 2026 25d ago | 8-K | $0.1531 $0.1300 | ▲ +15.09% | ▲ +16.25% | $0.1030 (+32.72%) |
Sep 23, 2026 4w ago | 8-K | $0.2280 $0.1530 | ▲ +32.89% | ▲ +32.22% | $0.1030 (+54.82%) |
Aug 11, 2026 10w ago | 8-K | $0.7190 $0.6460 | ▲ +10.15% | ▲ +9.75% | $0.1030 (+85.67%) |
Jul 13, 2026 15w ago | 10-K/A | $0.5710 $0.5300 | ▼ −7.18% | ▼ −6.40% | $0.1030 (−81.96%) |
May 21, 2026 22w ago | 8-K | $0.8410 $0.7699 | ▼ −8.45% | ▼ −10.13% | $0.1030 (−87.75%) |
May 12, 2026 23w ago | 8-K | $0.9230 $0.8830 | ▼ −4.33% | ▼ −4.41% | $0.1030 (−88.84%) |
Apr 27, 2026 26w ago | 8-K | $1.15 $0.9410 | ▼ −18.17% | ▼ −18.57% | $0.1030 (−91.04%) |
Apr 8, 2026 28w ago | 8-K | $1.41 $1.43 | ▲ +1.42% | ▼ −2.10% | $0.1030 (−92.70%) |
Apr 6, 2026 29w ago | EFFECT | $1.25 $1.33 | ▼ −6.40% | ▼ −2.27% | $0.1030 (+91.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers